Skip to main content

Table 1 Mean overall survival and progression-free survival in metastatic breast cancer subdivided on the basis of circulating tumor cell positivity

From: Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study

 

OS, months

95% CI, months

P value

PFS, months

95% CI, months

P value

Total

23.174

20.4-25.9

-

10.2

9.1-11.3

-

CellSearch™

      

   ≥1 CTC(s)

19.6

17.1-22.2

<0.01

9.8

8.5-11.0

n.s.

   <1 CTC

30.1

26.3-33.9

 

10.9

8.8-12.9

 

   ≥5 CTCs

18.1

15.1-21.1

<0.01

9.3

7.8-10.9

 

   <5 CTCs

27.1

23.5-30.7

 

10.9

9.3-12.5

n.s.

AdnaTest Breast™

      

   CTC-positive

19.3

15.4 - 23.1

n.s.

8.8

7.2-10.4

n.s.

   CTC-negative

23.8

20.3-27.5

 

10.7

9.2-12.2

 
  1. CTC, circulating tumor cell; n.s., not significant; OS, overall survival; PFS, progression-free survival.